How to Evaluate COVID-19 Vaccine Effectiveness—An Examination of Antibody Production and T-Cell Response
Funding
Conflicts of Interest
References
- Li, Y.; Tenchov, R.; Smoot, J.; Liu, C.; Watkins, S.; Zhou, Q. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent. Sci. 2021, 7, 512–533. [Google Scholar] [CrossRef] [PubMed]
- Wu, S.C. Progress and concept for COVID-19 vaccine development. Biotechnol. J. 2020, 15, e2000147. [Google Scholar] [CrossRef] [PubMed]
- Park, J.W.; Lagniton, P.N.; Liu, Y.; Xu, R.-H. mRNA vaccines for COVID-19: What, why and how. Int. J. Biol. Sci. 2021, 17, 1446. [Google Scholar] [CrossRef] [PubMed]
- Kaur, S.P.; Gupta, V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020, 288, 198114. [Google Scholar] [CrossRef] [PubMed]
- Strizova, Z.; Smetanova, J.; Bartunkova, J.; Milota, T. Principles and challenges in anti-COVID-19 vaccine development. Int. Arch. Allergy Immunol. 2021, 182, 339–349. [Google Scholar] [CrossRef] [PubMed]
- Krammer, F. SARS-CoV-2 vaccines in development. Nature 2020, 586, 516–527. [Google Scholar] [CrossRef] [PubMed]
- Fatima Amanat, F.K. SARS-CoV-2 Vaccines: Status Report. Immunity 2020, 52, 583–589. [Google Scholar] [CrossRef] [PubMed]
- Sui, Y.; Bekele, Y.; Berzofsky, J.A. Potential SARS-CoV-2 immune correlates of protection in infection and vaccine immunization. Pathogens 2021, 10, 138. [Google Scholar] [CrossRef] [PubMed]
- Britannica, T.E.O.E. Antibody. Available online: https://www.britannica.com/science/antibody (accessed on 22 May 2022).
- Zoppi, L. What Are Neutralizing Antibodies? Available online: https://www.news-medical.net/health/What-are-Neutralizing-Antibodies.aspx (accessed on 22 May 2022).
- Liu, L.; Wang, P.; Nair, M.S.; Yu, J.; Rapp, M.; Wang, Q.; Luo, Y.; Chan, J.F.-W.; Sahi, V.; Figueroa, A. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020, 584, 450–456. [Google Scholar] [CrossRef] [PubMed]
- Li, C.-J.; Chao, T.-L.; Chang, T.-Y.; Hsiao, C.-C.; Lu, D.-C.; Chiang, Y.-W.; Lai, G.-C.; Tsai, Y.-M.; Fang, J.-T.; Ieong, S. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion. Microbiol. Spectr. 2022, 10, e01814–e01821. [Google Scholar] [CrossRef] [PubMed]
- Jiang, S.; Hillyer, C.; Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020, 41, 355–359. [Google Scholar] [CrossRef] [PubMed]
- Cuffari, B. What Are Spike Proteins? Available online: https://www.news-medical.net/health/What-are-Spike-Proteins.aspx (accessed on 22 May 2022).
- Fraley, E.; LeMaster, C.; Geanes, E.; Banerjee, D.; Khanal, S.; Grundberg, E.; Selvarangan, R.; Bradley, T. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Med. 2021, 19, 169. [Google Scholar] [CrossRef]
- Genscript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit Instructions for Use; Genscript USA Inc.: Piscataway, NJ, USA, 2022. [Google Scholar]
- Altmann, D.M.; Boyton, R.J. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci. Immunol. 2020, 5, eabd6160. [Google Scholar] [CrossRef] [PubMed]
- Sahin, U.; Muik, A.; Derhovanessian, E.; Vogler, I.; Kranz, L.M.; Vormehr, M.; Baum, A.; Pascal, K.; Quandt, J.; Maurus, D. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020, 586, 594–599. [Google Scholar] [CrossRef]
- Kalimuddin, S.; Tham, C.Y.; Qui, M.; de Alwis, R.; Sim, J.X.; Lim, J.M.; Tan, H.-C.; Syenina, A.; Zhang, S.L.; Le Bert, N. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. Med 2021, 2, 682–688.e684. [Google Scholar] [CrossRef] [PubMed]
- Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.; Hafezi, M.; Chia, A.; Chng, M.H.Y.; Lin, M.; Tan, N.; Linster, M. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020, 584, 457–462. [Google Scholar] [CrossRef] [PubMed]
- Immunotec, O. T-SPOT.COVID Package Insert. Available online: https://www.tspotcovid.com/wp-content/uploads/sites/5/2021/03/PI-T-SPOT.COVID-IVD-UK-v3.pdf (accessed on 22 May 2022).
- Jaganathan, S.; Stieber, F.; Rao, S.N.; Nikolayevskyy, V.; Manissero, D.; Allen, N.; Boyle, J.; Howard, J. Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals. Infect. Dis. Ther. 2021, 10, 2765–2776. [Google Scholar] [CrossRef]
- Krüttgen, A.; Klingel, H.; Haase, G.; Haefner, H.; Imöhl, M.; Kleines, M. Evaluation of the QuantiFERON SARS-CoV-2 interferon-ɣ release assay in mRNA-1273 vaccinated health care workers. J. Virol. Methods 2021, 298, 114295. [Google Scholar] [CrossRef] [PubMed]
- QuantiFERON®. SARS-CoV-2 Extended Set Blood Collection Tubes Instructions for Use (Handbook); Qiagen: Germantown, MD, USA, 2021. [Google Scholar]
- QuantiFERON®. Control Set Blood Collection Tubes Instructions for Use (Handbook); Qiagen: Germantown, MD, USA, 2021. [Google Scholar]
- QuantiFERON®. SARS-CoV-2 Starter Set Blood Collection Tubes Instructions for Use (Handbook); Qiagen: Germantown, MD, USA, 2021. [Google Scholar]
- QuantiFERON®. ELISA Instructions for Use (Handbook); Qiagen: Germantown, MD, USA, 2021. [Google Scholar]
- Rudan, I.; Adeloye, D.; Sheikh, A. COVID-19: Vaccines, efficacy and effects on variants. Curr. Opin. Pulm. Med. 2022, 28, 180–191. [Google Scholar] [CrossRef] [PubMed]
- Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022, 23, 186–193. [Google Scholar] [CrossRef] [PubMed]
- Dornell, J. Humoral vs. Cell-Mediated Immunity. Available online: https://www.technologynetworks.com/immunology/articles/humoral-vs-cell-mediated-immunity-344829 (accessed on 22 May 2022).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fu, Y.-C.; Su, Y.-S.; Shen, C.-F.; Cheng, C.-M. How to Evaluate COVID-19 Vaccine Effectiveness—An Examination of Antibody Production and T-Cell Response. Diagnostics 2022, 12, 1401. https://doi.org/10.3390/diagnostics12061401
Fu Y-C, Su Y-S, Shen C-F, Cheng C-M. How to Evaluate COVID-19 Vaccine Effectiveness—An Examination of Antibody Production and T-Cell Response. Diagnostics. 2022; 12(6):1401. https://doi.org/10.3390/diagnostics12061401
Chicago/Turabian StyleFu, Yi-Chen, Ying-Shih Su, Ching-Fen Shen, and Chao-Min Cheng. 2022. "How to Evaluate COVID-19 Vaccine Effectiveness—An Examination of Antibody Production and T-Cell Response" Diagnostics 12, no. 6: 1401. https://doi.org/10.3390/diagnostics12061401
APA StyleFu, Y. -C., Su, Y. -S., Shen, C. -F., & Cheng, C. -M. (2022). How to Evaluate COVID-19 Vaccine Effectiveness—An Examination of Antibody Production and T-Cell Response. Diagnostics, 12(6), 1401. https://doi.org/10.3390/diagnostics12061401